The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity
By integrating IL15v into our anti-NKp46 based NKCEs, IL15v-NKCE has exhibited enhanced anti-tumor efficacy while maintaining an acceptable safety profile, thereby positioning it as a promising next-generation therapeutic modality for NK cell-based therapy.
Authors
- Shiyong Gong
- Baojun Shi (ORCID: https://orcid.org/0000-0001-6257-9749)
- Hongyan Lv (ORCID: https://orcid.org/0000-0002-4196-6982)
- Lijun Wang (ORCID: https://orcid.org/0009-0006-1322-0864)
- Yang Yang (ORCID: https://orcid.org/0000-0002-1290-6665)
- Rui Zhang (ORCID: https://orcid.org/0000-0003-4690-3945)
- Li Hu (ORCID: https://orcid.org/0000-0002-6657-4707)
- Xuan Wu
- Danqing Wu (ORCID: https://orcid.org/0009-0002-2711-4721)
- Zelong Ma (ORCID: https://orcid.org/0009-0001-8909-0246)
- Chengbin Wu (ORCID: https://orcid.org/0000-0001-6160-5327)
- Y. Ding (ORCID: https://orcid.org/0009-0002-5429-9995)
- Mengting Chen (ORCID: https://orcid.org/0000-0001-9379-6818)
Institutions
- Discovery Centre (CA)
- Shanghai Innovative Research Center of Traditional Chinese Medicine (CN)
- Shanghai Zhangjiang Laboratory (CN)
- Sab Biotherapeutics (United States) (US)
Publication Details
- Journal
- Antibody Therapeutics
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1093/abt/tbaf023
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00